Biotron Limited (ASX:BIT)

Australia · Delayed Price · Currency is AUD

0.0020

-0.0005 (-20.00%)

Sep 3, 2026, 9:59 AM AEST

Market Cap	5.57M +39.9%
Revenue (ttm)	525.87K -71.0%
Net Income	-1.52M
EPS	-0.00
Shares Out	2.79B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	218,333
Open	0.0030
Previous Close	0.0025
Day's Range	0.0020 - 0.0030
52-Week Range	0.0010 - 0.0050
Beta	-0.63
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 3, 2026

About Biotron

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company’s lead antiviral drug is BIT225 that is in Phase 2 clinical trial for the treatment of HIV-1, as well as to treat hepatitis C virus infections; and BIT-HBV001 to treat hepatitis B virus and hepatitis delta virus. It also develops preclinical drugs for viral diseases, such as dengue, zika, and influenza virus. The company was incorporated in 1999 and is based in Sydney, Australia. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1999

Employees 3

Stock Exchange Australian Securities Exchange

Ticker Symbol BIT

Full Company Profile

Financial Performance

In fiscal year 2026, Biotron's revenue was 525,869, a decrease of -71.00% compared to the previous year's 1.81 million. Losses were -1.52 million, 376.6% more than in 2025.

Financial Statements